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Abstract
Background: Indigenous Australians experience an overwhelming burden of chronic disease, including
cardiovascular diseases. Periodontal disease (inflammation of the tissues surrounding teeth) is also widespread, and
may contribute to the risk of cardiovascular diseases via pathogenic inflammatory pathways. This study will assess
measures of vascular health and inflammation in Indigenous Australian adults with periodontal disease, and
determine if intensive periodontal therapy improves these measures over a 12 month follow-up. The aims of the
study are: (i) to determine whether there is a dose response relationship between extent and severity of
periodontal disease and measures of vascular health and inflammation among Indigenous Australian adults with
moderate to severe periodontal disease; and (ii) to determine the effects of periodontal treatment on changes in
measures of vascular health and inflammation in a cohort of Indigenous Australians.
Methods/Design: This study will be a randomised, controlled trial, with predominantly blinded assessment of
outcome measures and blinded statistical analysis. All participants will receive the periodontal intervention benefits
(with the intervention delayed 12 months in participants who are randomised to the control arm). Participants will
be Indigenous adults aged ≥25 years from urban centres within the Top End of the Northern Territory, Australia.
Participants assessed to have moderate or severe periodontal disease will be randomised to the study’s
intervention or control arm. The intervention involves intensive removal of subgingival and supragingival calculus
and plaque biofilm by scaling and root-planing. Study visits at baseline, 3 and 12 months, will incorporate
questionnaires, non-fasting blood and urine samples, body measurements, blood pressure, periodontal assessment
and non-invasive measures of vascular health (pulse wave velocity and carotid intima-media thickness). Primary
outcome measures are pulse wave velocity and carotid intima-media thickness.
Discussion: The study will assess the periodontal-cardiovascular disease relationship among Indigenous Australian
adults with periodontal disease, and the effectiveness of an intervention aimed at improving periodontal and
cardiovascular health. Efforts to understand and improve Indigenous oral health and cardiovascular risk may serve
as an important means of reducing the gap between Indigenous and non-Indigenous health in Australia.
Trial Registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000817044
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Background
The health of Indigenous Australians
Indigenous Australians are disadvantaged on almost
every health and social indicator relative to their non-
Indigenous counterparts. They have 15-20 years shorter
life expectancy, much higher levels of cardiovascular dis-
ease, diabetes and other chronic conditions including
poor oral health status, and are more likely to experi-
ence disability and reduced quality of life due to ill
health [1-4]. They also have a high burden of infectious
diseases alongside significant rates of metabolic risk [5].
Cardiovascular disease
Cardiovascular diseases are a leading cause of morbidity
and mortality in developed countries. The disease process
that underlies the majority of cardiovascular events is
atherosclerosis, an inflammatory disease of the blood
vessel wall. The earliest physical evidence of atherosclero-
sis are fatty streaks, which are typically present in child-
hood. In the presence of arterial endothelial dysfunction,
which is involved in the initiation and progression of
atherosclerosis, these early lesions progress through to
complex atheromatous lesions in adulthood, finally
resulting in occlusion, plaque rupture and ischaemic
events [6].
Periodontal disease
Periodontal disease is inflammation of the tissues sur-
rounding teeth and results from a complex interplay
between bacteria and host risk factors such as long-term
smoking, poor oral hygiene, poorly controlled diabetes,
stress and genetic predisposition [7]. Not only have peri-
odontal organisms adapted to survive within an environ-
ment that is constantly besieged by host defences, but
they flourish in the presence of inflammation, enabling
their capacity to invade host tissues and gain direct
access to the circulation [8]. Repeated bacteremias and
endotoxemias are characteristic of periodontal infection,
and periodontal organisms have been found to co-localise
within atheromatous plaques [9]. The constant exposure
of the vasculature to these pathogens provides an oppor-
tunity for endothelial inflammatory activation and func-
tional impairment. Clinically, periodontal disease
manifests as deepening of the epithelial attachment
around teeth, loss of periodontal attachment and, ulti-
mately, tooth loosening.
Periodontal disease is widespread and poses a substan-
tial problem among Australian Aboriginal populations.
In Australia’s second National Survey of Adult Oral
Health (NSAOH), mild forms of periodontal disease were
reported to affect 20 percent of the adult population,
while more severe forms affected about 1 in 40 adults
[10], increasing to 3 in 10 adults when the Indigenous
population were considered in isolation. Similarly,
Endean and colleagues reported that among Aboriginal
adults seeking dental care in several Central Australian
remote communities, 30.2 percent had a history of this
condition [11]. The prevalence of tooth loss due to peri-
odontal disease among Aboriginal populations is also
high [12].
Periodontal disease has been associated with athero-
sclerosis [13], cardiovascular disease [14], diabetes [15],
pre-term low birth weight [16], stroke [17], and prema-
ture death [18]. Accordingly, periodontal disease may
account for a portion of the risk for cardiovascular dis-
ease via a shared pathogenic underlying inflammatory
response (figure 1) [8].
Periodontal therapy decreases systemic inflammation and
improves endothelial function
Treating periodontal disease results in a functional
improvement in cardiovascular status [19-22]. These
studies are consistent with the concept that periodontal
disease may be an important source of infectious and
inflammatory vascular stress, and that periodontal ther-
apy may be of particular clinical relevance in populations
with high prevalence of both periodontal disease and car-
diovascular disease.
Aims & hypotheses
The PerioCardio study will assess measures of vascular
health and inflammation in Indigenous Australian adults
with periodontal disease, and determine if intensive peri-
odontal therapy improves these measures over a 12
month follow-up. The specific aims and hypotheses are:
Aim 1: To describe the extent and severity of mea-
sures of vascular health and inflammation in Indigenous
Australian adults with moderate or severe periodontal
disease.
Hypothesis: The extent and severity of cardiovascular
surrogate endpoints in an Indigenous population with
periodontal disease will be high.
Aim 2: To determine whether there is a dose-response
relationship between extent and severity of periodontal
disease and measures of vascular health and inflamma-
tion among Indigenous Australian adults.
Hypothesis: The extent and severity of periodontal dis-
ease has a dose-response relationship with vascular
health and inflammatory measures.
Aim 3: To determine whether periodontal treatment
influences vascular health and inflammation in Indigen-
ous Australians with moderate to severe periodontal
disease.
Hypothesis: Periodontal therapy will improve vascular
health and inflammatory markers in Indigenous
Australians.
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Methods/design
Study design and overview
This will be a randomised, controlled trial, with predomi-
nantly blinded measurement of cardiovascular endpoints,
and blinded statistical analysis. All participants will
receive, or be offered, the periodontal intervention bene-
fits. A schema outlining the study design is presented in
Figure 2. The PerioCardio study has been registered with
an international clinical trials registry (ANZCTR;
ACTRN12610000817044), and will be reported as per
the CONSORT statement. Recruitment for the study
commenced in June 2010.
Setting & location
Participants will be recruited from urban centres within
the Top End of the Northern Territory, Australia, facili-
tated through the following Aboriginal Medical Services or
health facilities: Danila Dilba Health Services (Darwin and
Palmerston), Bagot Community Health Centre (Darwin),
Royal Darwin Hospital, Darwin Dental Centre (Northern
Territory Oral Health Services, Department of Health),
Northern Territory Correctional Services (Darwin), and
Wurli Wurlinjang (Katherine).
Participants and recruitment
Participants will be Indigenous Australians aged ≥25 years
that have lived in their current location for ≥2 years and
who plan to live at their current location for the next 2
years. Those participants who have moderate or severe
periodontal disease will be randomised to the intervention
or control arm of the study. Those participants without
periodontal disease, or only mild periodontal disease, will
not be included in the trial. Baseline questionnaires will,
however, be assessed in these participants in order to
study the social, demographic, lifestyle and general health
correlates of periodontal disease in Indigenous Australians.
Exclusion criteria include: a history of rheumatic heart
disease, prior myocardial infarction, stroke or coronary
revascularisation, other cardiac conditions requiring
antibiotic prophylaxis for prevention of subacute bacter-
ial endocarditis, obvious endodontic lesions, other
sources of oral infection, treatment for periodontal dis-
ease within the previous six months.
Feedback to participants will be provided at the end of
each examination. Participants with unexpected abnormal
results will be referred to an appropriate health care provi-
der. In addition, written results will be provided in a plain
language and culturally appropriate manner to individual
participants and to their nominated primary health care
provider. Whenever possible, participants with abnormal
results will be contacted by telephone or in person. The
results packet will then be mailed or hand-delivered, as
appropriate. A $50 gift voucher to a local store will be pro-
vided to participants at the end of the examination or with
their results as a gift of appreciation for their participation
in the study.
Funding
Funding was provided by the National Health and Medi-
cal Research Council of Australia (NHMRC, project
grant #627100).
Ethics
The study was approved by the joint Menzies School of
Health Research - Northern Territory Department of
Health Human Research Ethics Committee. The project
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Figure 1 Conceptual model of periodontal disease and cardiovascular surrogate endpoint response.
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was considered and approved by both the Aboriginal
sub-committee, which has absolute right of veto, and by
the main committee. The study was also approved by
the Central Australian Human Research Ethics Commit-
tee, Northern Territory Correctional Services Research
Committee, University of Adelaide Human Research
Ethics Committee, and the Aboriginal Health Council of
South Australia.
Staff
Three people are employed on contracts for the course of
the study. Of these, two are Indigenous and one is non-
Indigenous. Additional people are employed on a casual
basis during visits to discrete locations or communities;
these community members act as local facilitators. One
post-graduate research student also participates in the
study and is substantially involved in data collection, tak-
ing on the role of project manager. The majority of staff
members have prior health qualifications and experience:
one is an Aboriginal Health Worker, one has overseas
dental qualifications and the post-graduate research stu-
dent is an oral health therapist.
Consent
Potential participants are provided with written informa-
tion about the study, face-to-face discussion with a staff
member, and given an opportunity to ask questions. If
required, an interpreter explains all information relating
Approximately 450 Aboriginal adults screened; 266 with 
moderate to severe periodontal disease invited to participate 
266 undergo measures of vascular health and inflammation 
133 randomly selected 
to intervention group 
1st periodontal treatment 
(half mouth) 
2nd periodontal treatment 
(half mouth) 
133 randomly selected 
to control group 
3-month follow-up: measures of vascular health and inflammation 
12-month follow-up: measures of vascular health and inflammation 
Control group can opt to receive 
periodontal treatment at 12-month 
follow-up visit 
Figure 2 Study plan schema.
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to the study. Those who indicate that they wish to parti-
cipate are then asked to complete and sign a consent
form. Consent is obtained using the NHMRC Guidelines
for Ethical Conduct in Aboriginal and Torres Strait
Islander Health Research. All participants are informed
that their participation is voluntary and that they can
refuse or withdraw from participating and need give no
reason or justification for their decision and that it will
not affect their medical or dental care. Participants are
asked to provide separate consent for various elements
of the study, including: vascular assessments, blood and
urine samples, body measurements, blood pressure and
questionnaires. They are also asked whether they want a
report sent to their primary health care provider and
whether their blood and urine samples can be stored at
Menzies School of Health Research for 3 years.
Screening for periodontal disease
Following confirmation of contact details and eligibility,
and after obtaining informed consent, a participant will
be screened for periodontal disease, using the US Centers
for Disease Control and Prevention and the American
Academy of Periodontology definitions [23]. Thus, a case
of moderate periodontitis is considered as the presence
of either two sites between adjacent teeth with ≥4 mm
attachment loss or at least two such sites with ≥5 mm
pockets, and severe periodontitis as having at least two
sites between adjacent teeth with ≥6 mm attachment loss
and at least one pocket ≥5 mm.
Randomisation
After screening for periodontal disease, those with mod-
erate or severe periodontal disease are randomised on a
1:1 basis to either the treatment or control group. A
computer generated permuted block randomisation
sequence is used, stratified by recruitment site (Darwin/
Palmerston, Katherine).
Intervention
Individuals randomised into the ‘treatment group’
undergo a periodontal intervention based on the techni-
que described previously [20]. This involves intensive
removal of subgingival and supragingival calculus and
plaque biofilm by scaling and root-planing. Participants
are offered local anaesthesia prior to the procedure. The
procedures are carried out with the use of Hu Friedy
hand scalers and a piezoelectric ultrasonic scaler with
universal tips. Dental extraction of teeth that cannot be
saved is not performed as part of the treatment protocol.
The intervention is performed by two oral health practi-
tioners who have received additional training with these
techniques. The periodontal intervention occurs during a
single untimed visit to the study clinic.
Oral hygiene instruction and an oral hygiene pack
containing a toothbrush and tooth paste are provided to
all participants at the baseline visit. Information con-
cerning dental extractions during the course of the
study is recorded.
Participant involvement
Each participant randomised will attend the study clinic
a total of 3 times (figure 2).
Periodontal treatment will be offered to those in the
control group at 12 months post-randomisation, to ensure
that all participants are able to receive the oral health ben-
efits of the periodontal treatment. The periodontal treat-
ment offered to participants in this study is beyond that
which forms routine treatment within the government
funded system. Participants are not restricted from seeking
periodontal treatment during the study through the
private health system.
Data collection techniques
Dental assessment
including tooth presence, caries experience, periodontal
destruction, gingivitis and calculus, plaque, oral mucosal
lesions and trauma.
Clinical and anthropometric measures
Blood pressure is measured while seated using an auto-
mated device (Welch Allyn Medical Products, Skanea-
teles Falls, USA). Three measurements of systolic and
diastolic pressure are made, with three minutes between
readings. The mean values of the final two recordings
will be used in statistical analysis.
Height is measured to the nearest 0.1 cm using a wall-
mounted stadiometer.
Weight is measured to the nearest 0.1 kilogram, using a
portable weight scale (Tanita HD-351, Arlington Heights,
USA) with participants lightly clothed. Two separate
measurements of weight are recorded and if they differ,
then a third measurement of weight is taken.
Waist and hip circumference are measured to the near-
est 0.1 centimetre using a 2-metre non-stretch flexible
steel tape (Model W606PM Lufkin, USA), as previously
described [24].
Common carotid intima-media thickness (IMT) and M-mode
imaging
External ultrasound of the common carotid artery is per-
formed with the patient lying in a supine position, neck
slightly extended and the head tilted away from the side
being scanned whilst connected to 3-lead ECG, to monitor
cardiac cycle. Bilateral longitudinal images of the carotid
bulb and common carotid artery, up to 15 mm proximal
to the bulb, are obtained using a portable ultrasound
(Sonosite MicroMaxx, Bothell, USA), with a 10-5 MHz
linear array transducer. Loops are obtained of each artery,
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and stored in a digital format for batch analysis by an
observer blinded to participant group, characteristics and
study visit. Measurement of carotid IMT will be per-
formed on the far wall of the common carotid artery at
end diastole, within 10 mm proximal to the carotid bulb,
on two consecutive cardiac cycles.
M-mode imaging of the arterial diameter during the
cardiac cycle is used to assess regional stiffness of the
common carotid artery. The area of interest for the stiff-
ness measure is between 10 mm and 15 mm proximal to
the bulb. Loops of each side are obtained, ensuring that
both the near and far walls are clearly visible and the
artery is perpendicular to the angle of insonation. Inter-
nal diameter of the artery during systole and end-diastole
will be measured over three cardiac cycles to generate
the following indices: pressure-strain elastic modulus,
Young’s modulus, cross-sectional compliance, distensibil-
ity coefficient.
Pulse wave velocity (PWV)
PWV is measured between the common carotid and dor-
salis pedis arteries using applanation tonometry (Sphyg-
moCor-PVMx device, AtCor Medical, Sydney, Australia),
with participants in a supine position for at least 10 min-
utes prior to commencement of measures. The common
carotid artery is located via lateral palpation along the
thyroid cartilage while the dorsalis pedis artery is located
between the first and second metatarsals on the dorsal
surface of the foot. A pressure tonometer is placed trans-
cutaneously above the corresponding artery to record the
pulse pressure waveform while simultaneously recording
the ECG signal, which provides an R-wave timing refer-
ence. The arteries are assessed consecutively. The resul-
tant PWV score is calculated via computer algorithm as
the mean time difference between the R-wave and the
pressure wave per heart/pulse beat and the arterial path
length between the two recording sites. To correct
against measurement error, the distance from the com-
mon carotid location and the sternal notch will be sub-
tracted from the distance between the sternal notch and
the dorsalis pedis site. Data quality control for this mea-
surement requires that standard deviation not exceed
10%. In the instances that this occurs, PWV will be
remeasured. Measurement of PWV is undertaken auto-
matically by the acquisition machine, and as such the
observer will not be blinded to study participant
characteristics.
Blood and urine derived measures of cardiovascular risk
non-fasting blood and urine samples will be collected to
assess established measures of cardiovascular risk, inflam-
mation and vascular health, including glycosylated haemo-
globin (HbA1c), lipids and lipoproteins (total cholesterol,
high-density lipoprotein cholesterol, apolipoprotein A-1
and apolipoprotein B), high sensitivity C-reactive protein
(hs-CRP), interleukin-6 (IL-6), asymmetric dimethylargi-
nine (ADMA), and urine albumin to creatinine ratio.
Collected blood samples are centrifuged for 10 min at
1300 g within 30 minutes of collection. If unable to be
centrifuged immediately, blood is stored in a fridge or on
ice packs in a cool-box until centrifugation a maximum of
2-hours after collection. Following centrifugation, samples
are transported on ice to be processed by Westerns
Pathology, Darwin for lipids and HbA1c. Total cholesterol
is assayed by enzymatic methods, and high-density lipo-
protein cholesterol measured directly, with an ADVIA
chemistry system (Siemens, Tarrytown, USA). HbA1c is
determined by turbidimetric inhibition immunoassay with
a COBAS INTEGRA (Roche Diagnostics, Indianapolis,
USA). Other samples are stored at -80 degree Celsius. For
samples collected in remote locations, storage for trans-
portation is either on dry ice or in liquid nitrogen (“Biolo-
gical Shipper”, CryoPak Series, Taylor-Wharton, USA).
Samples are stored for analysis at a later date for hs-CRP,
IL-6, ADMA, apolipoproteins and glucose.
Self-administered questionnaires
Self-reported information pertaining to socio-demo-
graphic, oral health behaviours and general health fac-
tors is gathered at baseline, with the assistance of study
personnel as required.
Socio-demographic details include age, sex, Aboriginal/
Torres Strait Islander status, grandparental Indigenous
status, education level, employment, English-as-first-
language, house ownership, number of children, number
of people who stayed in house the previous night and car
ownership.
Oral health covariates include periodontal status and a
self-report item pertaining to whether or not partici-
pants think they have gum disease.
General health covariates include behaviours such as
smoking, current medication, current diagnoses (for dia-
betes etc), status of current diagnoses (controlled, uncon-
trolled etc) and stress (measured by the Kessler 10+ scale;
a validated measure of distress that has been validated in a
national health survey for Indigenous adults) [5].
Primary and secondary outcomes
The primary outcome measures for purposes of this
investigation will be carotid IMT and PWV. Secondary
outcome measures will include CRP, IL-6, ADMA, and
HbA1c.
Sample size
Based on recent studies of Indigenous adults residing in
the Northern Territory, we estimate that a sample size of
144 will provide 0.80 power to detect a 10 percent differ-
ence between groups in carotid IMT progression over
12-months, and a 10 percent reduction in PWV in the
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intervention group compared to the control group, at P <
0.05. The literature indicates that it is reasonable to
expect effects of this magnitude following the periodontal
intervention [25,26]. Allowing for an attrition rate of 45
percent over 12 months, 266 participants are required at
baseline. In NSAOH, the proportion of Aboriginal adults
with periodontal disease was estimated at 30 percent
[10], however, it is likely that Aboriginal participants in
NSAOH are not representative of the Aboriginal popula-
tion in which we are interested. There are two main rea-
sons: i) NSAOH participants were required to complete a
telephone interview (ie to have an operating telephone
and be registered in the electronic white pages); and ii)
NSAOH participants were required to organise their own
transport and to present for a scheduled dental examina-
tion at a local dental clinic. We posit that the NSAOH
estimate is an under-estimation of periodontal disease
prevalence in our target population, with anecdotal evi-
dence suggesting that the prevalence is closer to 60 per-
cent. We have estimated the prevalence of periodontal
disease in our target population as 40 percent, meaning
approximately 450 Indigenous adults will need to be
screened in order to obtain 266 with moderate or severe
periodontal disease.
Data handling and statistical methods
At the time of baseline assessment, data is collected on
paper forms and then entered into a Microsoft Access
database. Data is stored securely at Menzies School of
Health Research. In brief, the plan for the analysis is:
Aim 1: descriptive statistics including mean and standard
deviation for normally distributed variables, geometric
mean and 95% confidence interval for non-normally dis-
tributed data, and percentages for categorical variables.
Aim 2: associations of the extent and severity of peri-
odontal disease with measures of vascular health and
inflammation from cross-sectional analysis at baseline,
using correlation analysis, and multivariable regression
modelling adjusted for cardiovascular risk factors.
Aim 3: intention to treat analysis comparing cardiovas-
cular surrogate endpoints between the two randomised
groups. Primary outcomes are carotid IMT at 12-months
and PWV at both 3- and 12-months. Correlations between
the changes from baseline to 3- and 12-months in carotid
IMT, PWV and secondary outcomes will be determined.
Appropriate transformation of the data will be per-
formed as required. Crude correlations will be detailed,
followed by multivariable modelling. Statistical signifi-
cance will be inferred at 2P ≤ 0.05.
Discussion
The PerioCardio study will provide answers to three key
questions: (1) the extent of severity of cardiovascular
surrogate endpoints in an Indigenous adult population
with periodontal disease; (2) whether the extent and
severity of periodontal disease correlates with measures
of vascular health and inflammation in Indigenous
Australian adults and; (3) whether intense periodontal
therapy improves these markers of vascular health and
inflammation.
Furthermore the PerioCardio study will be the first
investigation examining the effectiveness of periodontal
therapy in changing cardiovascular surrogate endpoint
levels in an Indigenous Australian population, and the
first investigation to monitor changes in cardiovascular
surrogate endpoints following periodontal intervention
at both 3- and 12-months.
As such, the PerioCardio study will have significance
for policy and planning by providing evidence of the
relationship between periodontal disease, periodontal
therapy, and cardiovascular disease among Indigenous
Australian adults with periodontal disease, and the
effectiveness of an intervention aimed at improving per-
iodontal and cardiovascular health in an Indigenous
population. Efforts to understand and improve Indigen-
ous oral health and cardiovascular risk may serve as an
important means of reducing the gap between Indigen-
ous and non-Indigenous health in Australia.
The findings may help raise the profile of the role of
periodontal disease in cardiovascular health; thus increas-
ing the knowledge base of those working intimately with
patients with cardiovascular disease. Ultimately it is
hoped that the findings might encourage greater dialogue
between oral health and medical professionals so that
periodontal treatment might become a routine part of
care in the treatment of cardiovascular disease among
Indigenous as well as non-Indigenous populations.
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